Doripenem monohydrate NEW
Price | $29 | $44 | $74 |
Package | 10mg | 25mg | 50mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-14 |
Product Details
Product Name: Doripenem monohydrate | CAS No.: 364622-82-2 |
Purity: 99% | Supply Ability: 10g |
Release date: 2024/11/14 |
Product Introduction
Bioactivity
名稱 | Doripenem monohydrate |
描述 | Doripenem monohydrate (S 4661 monohydrate) is a broad-spectrum injectable antibiotic, used for Gram-positive, Gram-negative and anaerobic pathogens. |
體外活性 | Doripenem is active against Aeromonas (MIC50, 0.03 mg/L), Bacillus spp. (MIC50, 0.03 mg/L) and all tested anaerobic species (MIC range, < or =0.015-4 mg/L), but is less active against S. maltophilia (MIC90, >32 mg/L) and Enterococcus faecium (MIC90, >32 mg/L) among the enterococcal species. [1] Doripenem is the most active carbapenem (MIC90, 1 to 4 mg/mL) against penicillin-resistant streptococci. [2] Doripenem is found to be highly active against oxacillin-susceptible Staphylococcus aureus and coagulase-negative staphylococci (2705 and 297 isolates, respectively; MIC90s 0.06 mg/L), with a potency greater than that of other carbapenem antibiotics. Doripenem is among the most potent agents tested against Streptococcus pneumoniae, viridans group streptococci and beta-haemolytic streptococci (885, 140 and 397 isolates; MIC(90)s 0.5, 0.5 and 0.03 mg/L, respectively). Doripenem is also active against Citrobacter spp., Enterobacter spp. and Serratia spp. (MIC90s 0.06-0.25 mg/L), including ceftazidime-resistant isolates. Doripenem is slightly more potent (MIC50 2 mg/L) than ertapenem and imipenem (MIC50 4 mg/L), and has a potency similar to that of meropenem (MIC50 2 mg/L), against Burkholderia cepacia (20 isolates). [3] Doripenem demonstrates in vitro activity similar to that of meropenem against gram-negative pathogens and to that of imipenem against gram-positive pathogens. [4] |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 34 mg/mL (77.5 mM) H2O : 24 mg/mL (54.7 mM) |
關(guān)鍵字 | S4661 | Antibiotic | Inhibitor | Bacterial | S 4661 Monohydrate | Doripenem monohydrate | Doripenem Monohydrate | inhibit | S-4661 Monohydrate | S 4661 | Doripenem | S4661 Monohydrate |
相關(guān)產(chǎn)品 | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Methyl anthranilate | Kanamycin sulfate | G-418 disulfate | Sulfamethoxazole sodium | Metronidazole | Doxycycline | EDTA copper(II) disodium salt | Dimethyl sulfoxide | Crystal Violet |
相關(guān)庫 | 經(jīng)典已知活性庫 | EMA 上市藥物庫 | 藥物功能重定位化合物庫 | 抗菌活性庫 | FDA 上市藥物庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$29.00/10mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-14 | |
$11.00/1kg |
Hebei baicao biology science and technology co., ltd
|
2022-04-02 | ||
$15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-11 | ||
$0.00/1g |
Beijing Yibai Biotechnology Co., Ltd
|
2019-08-16 | ||
$7.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-21 | |
$15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-09 | ||
$15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-06-26 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY